Developing a Novel Assay for Circulating Multiple Myeloma Cells Using the CELLSEARCH Platform, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss why circulating multiple myeloma cells (CMMC) are a potential biomarker for disease progression in multiple myeloma and how CMMC counts correlate with traditional disease markers. Attendees will also learn about non-invasive liquid biopsy replacement for traditional bone marrow biopsies.

Patient studies with the assay have shown that CMMC counts correlate with clinical measures of disease burden, including percentage of bone marrow plasma cells, serum M protein, and International Staging System stage.

Multiple myeloma is the second most prevalent hematological cancer in the United States, with approximately 30,000 new cases a year. At present, the disease remains incurable with a 5-year survival rate of 51%. To aid in the understanding of the biology of multiple myeloma and monitor clinical progression of the disease, a novel assay was developed using the CELLSEARCH® system to isolate and enumerate circulating multiple myeloma cells (CMMC) from peripheral blood.

Patient studies with the assay have shown that CMMC counts correlate with clinical measures of disease burden, including percentage of bone marrow plasma cells, serum M protein, and International Staging System stage. Patients with CMMC counts ≧ 100 in 4 mL blood during remission had worse progression-free survival compared with patients who had less than 100. Studies looking at the precursor disease state, smoldering multiple myeloma (SMM) showed that higher patient CMMC counts were associated with higher-risk myeloma states. This demonstrates the power of enumerating CMMC as a potential marker for disease progression and stage in a minimally-invasive assay.

Join Dr. Irene Ghobrial, M.D., DFCI, Director, Clinical Investigator Research Program at Dana-Farber Cancer Institute; Steven Gross, Head of Assay Development, Menarini Silicon Biosystems; and Sara Lazaro, Head of Clinical Lab Operations and Services, Menarini Silicon Biosystems in a live webinar on Friday, November 20, 2020 at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Developing a Novel Assay for Circulating Multiple Myeloma Cells Using the CELLSEARCH Platform.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
Xtalks
+1 (416) 977-6555 x 352
Email >
Visit website